Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.50	$3.65	$3.96 ▼ $12.00	$6.28M	1.55	7,305 shs	1,182 shs
JATT JATT Acquisition	$1.72 +8.2%	$1.36	$7.80 ▼ $12.38	$29.67M	N/A	41,322 shs	378,508 shs
RNTX Rein Therapeutics	$1.19 +3.4%	$1.45	$1.04 ▼ $4.40	$26.62M	1.31	61,382 shs	51,067 shs
TPST Tempest Therapeutics	$10.53 +11.1%	$7.32	$5.33 ▼ $20.67	$42.09M	-1.93	103,767 shs	223,029 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	-1.69%	-7.16%	-3.31%	+4.79%	-45.44%
JATT JATT Acquisition	+8.16%	+1.27%	+22.31%	+32.50%	-51.67%
RNTX Rein Therapeutics	-3.75%	+4.05%	-17.50%	-47.74%	+115,499,900.00%
TPST Tempest Therapeutics	+1.50%	+34.85%	+41.70%	+38.39%	-38.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	2.2475 of 5 stars	3.3	2.0	0.0	0.0	4.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
JATT JATT Acquisition	0.00	N/A	N/A	N/A
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A
TPST Tempest Therapeutics	2.50	Moderate Buy	$30.00	184.90% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.64	N/A	N/A	$14.99 per share	0.23
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.46 per share	2.58	$0.43 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$2.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-110.77%	-31.89%	N/A
TPST Tempest Therapeutics	-$41.84M	-$14.59	N/A	N/A	N/A	N/A	-334.76%	-130.63%	N/A

Latest AEZS, RNTX, TPST, and JATT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/11/2025	Q2 2025	TPST Tempest Therapeutics	-$3.23	-$2.07	+$1.16	-$2.07	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
JATT JATT Acquisition	N/A	0.15	0.15
RNTX Rein Therapeutics	N/A	1.39	1.39
TPST Tempest Therapeutics	N/A	2.12	1.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
JATT JATT Acquisition	47.97%
RNTX Rein Therapeutics	90.89%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
JATT JATT Acquisition	20.00%
RNTX Rein Therapeutics	5.10%
TPST Tempest Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
RNTX Rein Therapeutics	9	23.05 million	21.87 million	N/A
TPST Tempest Therapeutics	20	4.44 million	4.23 million	Optionable

AEZS, RNTX, TPST, and JATT Headlines

Recent News About These Companies

Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12 at 5:27 AM | finanznachrichten.de

Tempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495

August 11, 2025 | quiverquant.comQ

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025 | globenewswire.com

Morpheus-Liver Study: A New Horizon in Advanced Liver Cancer Treatment

August 4, 2025 | tipranks.com

Tempest Therapeutics’ Promising Advances in Liver Cancer Treatment

July 3, 2025 | tipranks.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - Nasdaq

July 2, 2025 | nasdaq.com

Tempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China

June 30, 2025 | quiverquant.comQ

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

June 30, 2025 | globenewswire.com

TPST - Tempest Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

TPST Tempest Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Tempest announces $4.6 million registered direct offering of common stock; shares decline over 13%

June 11, 2025 | msn.com

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | quiverquant.comQ

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

June 11, 2025 | globenewswire.com

Tempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic Alternatives

June 7, 2025 | marketwatch.com

Tempest Therapeutics Shares Up, Executive Team Enters Into Consulting Agreements

June 7, 2025 | marketwatch.com

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

June 6, 2025 | zacks.com

Tempest Therapeutics stock rises on EMA Orphan Drug Designation

June 5, 2025 | au.investing.com

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

June 5, 2025 | globenewswire.com

Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEZS, RNTX, TPST, and JATT Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$3.50 0.00 (0.00%)

As of 08/14/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

JATT Acquisition NYSE:JATT

$1.72 +0.13 (+8.18%)

As of 08/14/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Rein Therapeutics NASDAQ:RNTX

$1.19 +0.04 (+3.38%)

As of 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Tempest Therapeutics NASDAQ:TPST

$10.53 +1.05 (+11.08%)

Closing price 04:00 PM Eastern

Extended Trading

$10.62 +0.10 (+0.90%)

As of 07:59 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time